Studies have reported that the expression of SETDB1 significantly increases the risk of melanoma (Ceol et al., 2011), lung cancer (Lindgren et al., 2012), urothelial carcinoma (Wong et al., 2012), glioma (Spyropoulou et al., 2014), ovarian cancer (Hua et al., 2014), prostate cancer (Sun et al., 2014), breast cancer (Liu et al., 2015), hepatocellular carcinoma (Wong et al., 2016), colorectal cancer (Chen et al., 2017), and solid tumors (Huang et al., 2018). Here, SETDB1 is linked to prostate cancer.